c-Abl Inhibitors Enable Insights into the Pathophysiology and Neuroprotection in Parkinson’s Disease-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

c-Abl Inhibitors Enable Insights into the Pathophysiology and Neuroprotection in Parkinson’s Disease

Published:2016-10-26 Issue: Volume:8 Page:
ISSN:1663-4365
Container-title:Frontiers in Aging Neuroscience
language:
Short-container-title:Front. Aging Neurosci.

Author:

Lindholm Dan,Pham Dan D.,Cascone Annunziata,Eriksson Ove,Wennerberg Krister,Saarma Mart

Funder

Pfizer

Suomen Akatemia

Sigrid Juséliuksen Säätiö

Finska Läkaresällskapet

Magnus Ehrnroothin Säätiö

Publisher

Frontiers Media SA

Subject

Cognitive Neuroscience,Aging

Reference48 articles.

1. Does ponatinib cross the blood-brain barrier?;Abid;Br. J. Haematol.,2016

2. Motor and cognitive advantages persist 12 months after exenatide exposure in Parkinson’s disease;Aviles-Olmos;J. Parkinsons Dis.,2014

3. Activation of tyrosine kinase c-Abl contributes to α-synuclein-induced neurodegeneration;Brahmachari;J. Clin. Invest.,2016

4. Basic science breaks through: new therapeutic advances in Parkinson’s disease;Brundin;Mov. Disord.,2015

5. Glivec (STI571, imatinib), a rationally developed, targeted anticancer drug;Capdeville;Nat. Rev. Drug Discov.,2002

Cited by 35 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. An update on novel and emerging therapeutic targets in Parkinson’s disease;Metabolic Brain Disease;2024-07-27

2. Prophylactic treatment with the c-Abl inhibitor, neurotinib, diminishes neuronal damage and the convulsive state in pilocarpine-induced mice;Cell Reports;2024-05

3. The c-Abl-RACK1-FAK signaling axis promotes renal fibrosis in mice through regulating fibroblast-myofibroblast transition;Cell Communication and Signaling;2024-04-30

4. A recent update on drugs and alternative approaches for parkinsonism;Neuropeptides;2024-04

5. Glutamate Receptors and C-ABL Inhibitors: A New Therapeutic Approach for Parkinson's Disease;Central Nervous System Agents in Medicinal Chemistry;2024-04

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3